Skip Navigation



JAC Advance Access published online on April 19, 2008

Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkn158
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
62/1/122    most recent
dkn158v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kechagia, N.
Right arrow Articles by Chatzipanagiotou, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kechagia, N.
Right arrow Articles by Chatzipanagiotou, S.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Original research

Incidence and antimicrobial susceptibilities of genital mycoplasmas in outpatient women with clinical vaginitis in Athens, Greece

Nektaria Kechagia1, Sotiris Bersimis2 and Stylianos Chatzipanagiotou3,*

1 Alimos Medifirst, Medical Group Practise, Department of Biopathology, Athens, Greece 2 Department of Informatics with Applications in Biomedicine, University of Central Greece, Lamia, Greece 3 Athens Medical School, Aeginition Hospital, Department of Biopathology and Clinical Microbiology, Athens, Greece

Received 24 January 2008; returned 12 March 2008; revised 6 March 2008; accepted 14 March 2008


* Corresponding author. Tel: +30-210-7289192; Fax: +30-210-6004608; E-mail: chatlouk{at}hotmail.com/ schatzi{at}med.uoa.gr

Objectives: The incidence and antimicrobial susceptibilities of Ureaplasma urealyticum and Mycoplasma hominis, isolated from vaginal and endocervical swabs collected from 369 outpatient women, were determined.

Methods: Isolation, identification and typing of the pathogens were performed by means of conventional methods. The antimicrobial susceptibilities of the genital mycoplasmas were determined with commercially available kits and evaluated according to the CLSI.

Results and conclusions: In 65 (47.44%) out of the 137 positive specimens, U. urealyticum was grown as a single pathogen, in 0.72% M. hominis was grown as a single pathogen and in 2.92% both urogenital mycoplasmas were grown. In the remaining specimens (48.90%), there was a mixed growth with other microbes. Of the isolated U. urealyticum strains, 87.4% and 98.2% were susceptible to tetracycline and doxycycline, respectively, 79.2% were susceptible to josamycin, 48.6% were susceptible to clarithromycin and 91.8% were susceptible to pristinamycin, while erythromycin, azithromycin, ciprofloxacin and ofloxacin proved to be inactive against most of the strains. M. hominis isolates were 100% susceptible to tetracycline, doxycycline and pristinamycin, while susceptibilities to the other antimicrobial agents varied mainly in the range of ‘intermediate’ or ‘resistant’. As results originating from similar studies from various countries are very controversial, the simplest way to avoid therapeutic failures would be the implementation of rational treatment regimens based on culture isolation and the in vitro determination of the antimicrobial susceptibility of genital mycoplasmas in each clinical case.

Key Words: Mycoplasma hominis , Ureaplasma urealyticum , susceptibility


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.